Clinical Microbiology and Infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines N. Aliabadi, J.E. Tate, U.D. Parashar Clinical.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

L. Boyanova Clinical Microbiology and Infection

Activity of imipenem against VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model G.L. Daikos, A. Panagiotakopoulou,

Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines N. Aliabadi, J.E. Tate, U.D. Parashar Clinical.

Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period J. Liñares, C. Ardanuy, R. Pallares, A.

Human papilloma viruses and cancer in the post-vaccine era

Approach to diagnosis of infective endocarditis

Varicella vaccination: a laboured take-off

S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler

Clinical Microbiology and Infection

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Oral presentations Clinical Microbiology and Infection

E. Lindberg, I. Adlerberth, A.E. Wold

Discrepancies between general practitioners' vaccination recommendations for their patients and practices for their children N. Agrinier, M. Le Maréchal,

R. Cantón Clinical Microbiology and Infection

Louis Pasteur, from crystals of life to vaccination

General infection control issues

Use of surveillance cultures and enteral vancomycin to control methicillin-resistant Staphylococcus aureus in a paediatric intensive care unit K. Thorburn,

Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. H. Wisplinghoff, H. Seifert,

Surveillance of Legionnaires’ disease in Austria

W. Witte, B. Pasemann, C. Cuny Clinical Microbiology and Infection

Clinical Microbiology and Infection

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

The role of vaccination in preventing pneumococcal disease in adults

Do we need new antibiotics?

Y. Maor, N. Belausov, D. Ben-David, G. Smollan, N. Keller, G. Rahav

Carl Erik Nord, Ann Lidbeck, Kerstin Orrhage, Svante Sjöstedt

A. Solé, P. Morant, M. Salavert, J. Pemán, P. Morales

Clinical Microbiology and Infection

Enhanced surveillance of carbapenemase-producing Gram-negative bacteria to support national and international prevention and control efforts R. Freeman

Training for the infectious diseases speciality in Norway

Epidemiology of opportunistic infections in AIDS patients

Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines N. Aliabadi, J.E. Tate, U.D. Parashar Clinical.

Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections

G. Pappas Clinical Microbiology and Infection

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults* P. Durando, S.N. Faust,

Effect of antioxidants on the immune response of Helicobacter pylori

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Symposia and Oral Presentations

Streptococcus pneumoniae serotype 1 causing invasive disease among children in Barcelona over a 20-year period (1989–2008) C. Esteva, L. Selva, M.F.

Pathogenesis of catheter-related infections: lessons for new designs

Y. Tveten, A. Jenkins, A.G. Allum, B.-E. Kristiansen

Antibacterial drug discovery in the 21st century

Community-acquired pneumonia: epidemiologic and clinical consideration

Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals G.L. Cartolano,

P.M. Hawkey Clinical Microbiology and Infection

Strain relatedness of meticillin-resistant Staphylococcus aureus isolates recovered from patients with repeated bacteraemia C-H. Liao, C-C. Lai, S-Y.

Current experience in treating invasive zygomycosis with posaconazole

Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia M.-S. Hsu,

Effect of antibiotics, alone and in combination, on Panton–Valentine leukocidin production by a Staphylococcus aureus reference strain O. Dumitrescu,

M.B. Kerrn, N. Frimodt-Møller, F. Espersen

Clinical Microbiology and Infection

The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae I. Gustafsson, O. Cars Clinical Microbiology.

Rise and subsequent decline of community-associated methicillin resistant Staphylococcus aureus ST30-IVc in Copenhagen, Denmark through an effective search.

E. Tacconelli Clinical Microbiology and Infection

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

A. Manzur, F. Gudiol Clinical Microbiology and Infection

Abstracts accepted for publication only

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Clinical microbiological case: thermointolerant microorganism growth in blood cultures and catheter tip M. Blasco-Navalpotro, M. Jordán, J.J. Camarena,

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Clinical Microbiology and Infection

Presentation transcript:

Clinical Microbiology and Infection Oral presentations Clinical Microbiology and Infection Volume 17, Pages S1-S107 (May 2011) DOI: 10.1111/j.1469-0691.2011.03557.x Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Figure 1 In vivo activity of ClyS ointment vs. placebo or mupirocin on tape-stripped mice infected with S. aureus 8325–4 or MRSA MW2. Topical treatrnents included Aquaphor® (control), 10% ClyS binding domain in Aquaphor® (placebo), 10% wt/wt ClyS in Aquaphor®, and 2% mupirocin. The median value of the data for each group is shown as a horizontal bar; each sphere represents one mouse. No statistical significance was seen between untreated, control, and placebo groups. Statistical significance (p < 0.0001) was noted between untreated/control/placebo and ClyS groups with a three log drop in bacteria recovered (CFUs). Statistical difference (p = 0.001) was noted between ClyS and mupirocin treated groups, with a one log drop difference between them. Figure is representative of experiments using S. aureus strain 8325–4 or MRSA strain MW2. Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Fig. 1 Percent of cultures from the five high touch sites that were negative for aerobic growth after decontamination with the HPV and UVC process. Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Figure 1 Implementation of policy elements covered by the survey questionnai re Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Figure 1 Pneumococcal vaccination and invasive pneumococcal disease 2002–2009. Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions

Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10. 1111/j Clinical Microbiology and Infection 2011 17, S1-S107DOI: (10.1111/j.1469-0691.2011.03557.x) Copyright © 2011 Terms and Conditions